Covered recipient · General Payments record
ROCIO KRYSTAL RIVERA-VALENTIN
Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology
General Payments · PY2022–2024
$2,523.81
- Reported across 19 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,822.56 | 4 |
| Food and Beverage | $688.84 | 14 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| CSL Behring | $2,469.93 | 16 |
| Fennec Pharmaceuticals, Inc. | $41.47 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| CSL Behring | $806.55 | 04/27/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1134629165 | CMS |
| CSL Behring | $110.11 | 04/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629169 | CMS |
| CSL Behring | $76.80 | 04/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629177 | CMS |
| CSL Behring | $23.77 | 04/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629187 | CMS |
| CSL Behring | $67.67 | 04/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629189 | CMS |
| CSL Behring | $874.06 | 04/28/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1134629205 | CMS |
| CSL Behring | $32.86 | 04/28/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1134629207 | CMS |
| CSL Behring | $46.31 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629223 | CMS |
| CSL Behring | $120.60 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629231 | CMS |
| CSL Behring | $25.28 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629239 | CMS |
| CSL Behring | $10.78 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629253 | CMS |
| CSL Behring | $8.46 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629255 | CMS |
| CSL Behring | $109.09 | 04/29/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1134629267 | CMS |
| CSL Behring | $62.21 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629275 | CMS |
| CSL Behring | $72.75 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629283 | CMS |
| CSL Behring | $22.63 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134629291 | CMS |
| Fennec Pharmaceuticals, Inc. | $20.74 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120185216 | CMS |
| Fennec Pharmaceuticals, Inc. | $20.73 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120185218 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.